StageIPO | IPO
Date of IPO3/2/2020
About Qlife Holding
Qlife is a high-tech medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it the most. Its main product, The Egoo Home System, is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient’s doctor, clinic or hospital via smartphone and computer. Qlife is headquartered in Helsingborg, Sweden.
Missing: Qlife Holding's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Qlife Holding's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Qlife Holding
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Qlife Holding is included in 4 Expert Collections, including Health Monitoring & Diagnostics.
Health Monitoring & Diagnostics
At-home IVD test developers, at-home sample collection device developers, at-home testing service providers, and all other companies playing in the at-home testing ecosystem. Companies tagged as #AtHomeTestingEcosystem
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Latest Qlife Holding News
Mar 24, 2023
Qlife Holding AB Fri, Mar 24, 2023 14:45 CET Resolution on amendment of the Articles of Association The extraordinary general meeting resolved in accordance with the proposal from the board of directors to amend the provisions in the Articles of Association regarding the limits for the company’s share capital and the number of shares. The limits that are ultimately registered at the Swedish Companies Registration Office (Sw. Bolagsverket) depend on the number of shares subscribed and paid for in the Rights Issue (see definition below). Resolution on approval of the board of directors’ resolution on rights issue of units The extraordinary general meeting resolved in accordance with the proposal from the board of directors to approve the board of directors’ resolution of 16 February 2023 on a rights issue of a maximum of 576,813,400 units (the “Rights Issue”). Those who are registered as shareholders in the company on the record date 5 April 2023 will receive twenty-five (25) unit rights per existing share. One (1) unit right entitles to subscription of one (1) unit in the company at a subscription price of SEK 0.1 per unit, which corresponds to a subscription price of SEK 0.1 per share. Each unit consists of one (1) new share and one (1) warrant series TO 3 (“TO 3”). In total, the issue comprises a maximum of 576,813,400 shares and a maximum of 576,813,400 TO 3. One (1) TO 3 entitles the right to acquire one (1) new share in the company against cash consideration amounting to SEK 0.11 per share. The TO 3 may be exercised during the period from and including 11 September 2023 up to and including 29 September 2023. Upon full subscription of all shares that are issued in the Rights Issue, the company’s share capital will increase with a maximum of SEK 46,145,072. Upon full subscription of all TO 3 that are issued in the Rights Issue, the company’s share capital will increase with a maximum of SEK 46,145,072. The subscription period in the Rights Issue runs from and including 11 April 2023 up to and including 25 April 2023. Resolution on authorization for the board of directors to resolve on issues The extraordinary general meeting resolved, in accordance with the proposal from the board of directors, to authorize the board of directors in accordance with the following. The board of directors shall be authorized, at one occasion, during the period up until the next annual general meeting, to resolve on a new issue of additional units consisting of shares and warrants in the event of over-subscription in the Rights Issue. The issue can be made with or without provisions regarding payment in cash, set-off or other provisions. The authorization can only be used to carry out a so called ”over-allotment issue”. The total number of shares and warrants that may be issued pursuant to the authorization under this item 1 shall not exceed 50,000,000 shares and 50,000,000 warrants. The right to subscribe for the new shares and warrants shall, with deviation from the shareholders’ preferential rights, primarily vest with strategic and professional investors which have subscribed for units in the Rights Issue without receiving full allotment. An issue resolved upon in accordance with this item 1 shall be made on the same main terms as in the Rights Issue. The purpose of the authorization and the reason for the deviation from the shareholders’ preferential rights under this item 1 is to be able to satisfy any over-subscription in the Rights Issue and thereby provide the company with additional capital contributions and strategic and professional investors and to provide the opportunity for increased distribution in the company's share. In order to enable new issues of units consisting of shares and warrants as guarantee compensation to persons who have entered into guarantee commitments (the ”Guarantors”) to secure the Rights Issue, the board of directors shall, on one or more occasions, during the period up until the next annual general meeting, with deviation from the shareholders' preferential rights and with or without provisions regarding payment in cash, set-off or other provisions, be authorized to resolve on new issues of shares and warrants to the Guarantors. Upon exercise of the authorization under this item 2, the subscription price for units shall be the same as in the Rights Issue. The purpose of the authorization and the reason for the deviation from the shareholders’ preferential rights under this item 2 is to be able to carry out an issue of units as guarantee compensation to the Guarantors. The number of shares and warrants that may be issued pursuant to the authorization may not exceed the total number of shares and warrants corresponding to the agreed guarantee compensation that the company shall pay to the Guarantors. The remaining issue terms in accordance with the items above shall be determined by the board of directors. Helsingborg on 24 March 2023 Qlife Holding AB (publ) The information was submitted for publication, through the agency of the contact person, on 24-03-2023 14:45 CET. For more information please contact: Mette Gross, Chair Qlife Holding AB Tel. No. : +46 (0)73-517 85 25 Qlife is a medical device company born to challenge the status quo in healthcare. We work to shift the perspective and turn today's view on healthcare into tomorrow's focus on health- empowerment. We are on a quest to empower people with more accessible ways to understand their health - so that they can move beyond reactive care towards proactive wellbeing. It's how we contribute to improving quality of life for every individual and for the greater society. Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor. Read more on Egoo.health , Qlifeholding.com or follow us on LinkedIn .
Qlife Holding Frequently Asked Questions (FAQ)
Where is Qlife Holding's headquarters?
Qlife Holding's headquarters is located at Hamntorget 3, Helsingborg.
What is Qlife Holding's latest funding round?
Qlife Holding's latest funding round is IPO.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.